Incidence of Venous Thromboembolism in Patients With Pelvic and Acetabular Fractures (PAF)
PAF-VTE
Venous Thromboembolism in Pelvic Ring and Acetabular Fractures - A Prospective Cohort Study
1 other identifier
observational
81
1 country
1
Brief Summary
The goal of this observational study is to investigate the incidence of venous thromboembolism (VTE) in patients with pelvic and acetabular fractures (PAF). The main question it aims to answer is: What is the incidence of VTE in PAF patients receiving standardized thromboprophylaxis with enoxaparin 4,000 IU twice daily? Participants admitted with a pelvic, acetabular, or combined fracture receive thromboprophylaxis as part of their routine clinical care. All participants undergo bilateral duplex ultrasound screening during hospitalization to detect both symptomatic and asymptomatic deep vein thrombosis. If pulmonary embolism is clinically suspected, computed tomography pulmonary angiography is performed. The study aims to provide prospective observational data on VTE incidence and its association with fracture type, patient risk profile, and treatment modality.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedFirst Submitted
Initial submission to the registry
September 1, 2025
CompletedFirst Posted
Study publicly available on registry
September 10, 2025
CompletedSeptember 10, 2025
September 1, 2025
1 year
September 1, 2025
September 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of venous thromboembolism (VTE) during hospital stay
Detection of symptomatic and asymptomatic VTE (deep vein thrombosis or pulmonary embolism) during index hospitalization, assessed by routine duplex ultrasound and clinical imaging.
Conservative: 48h, days 3-6 post-trauma. Operative: ≤48h post-trauma, postop days 2-5. Baseline only if admitted ≤48h. Additional exams if clinical suspicion of VTE during hospitalization.
Secondary Outcomes (2)
Bleeding complications
From admission until hospital discharge (up to 60 days); bleeding events were continuously monitored throughout the entire index hospitalization.
Association of VTE with fracture type and treatment modality
VTE assessed during index hospitalization: conservative patients at 48h and days 3-6 post-trauma; operative patients at ≤48h post-trauma and postop days 2-5; additional exams if clinical suspicion, until discharge (up to 60 days).
Study Arms (1)
Patients with pelvic and/or acetabular fractures
Adult patients (≥18 years) admitted with pelvic, acetabular, or combined fractures. All participants receive standardized thromboprophylaxis with enoxaparin 4,000 IU twice daily as part of routine clinical care and undergo duplex ultrasound screening during hospitalization
Interventions
Bilateral duplex ultrasound screening performed during hospitalization to detect symptomatic and asymptomatic deep vein thrombosis in patients with pelvic and acetabular fractures.
Eligibility Criteria
Adult patients (≥18 years) admitted to the BG Trauma Center at the University Hospital Tübingen with acute pelvic, acetabular, or combined pelvic-acetabular fractures. All participants received standardized thromboprophylaxis with enoxaparin 4,000 IU twice daily and underwent systematic duplex ultrasound screening during hospitalization.
You may qualify if:
- Adults ≥18 years
- Patients admitted with pelvic ring, acetabular, or combined pelvic-acetabular fracture
- Received thromboprophylaxis with enoxaparin 4,000 IU twice daily
- Hospital admission within the screening period
- Informed consent
You may not qualify if:
- Pathological fractures
- Thrombophilia
- Pre-existing oral anticoagulation
- Dementia
- Thromboprophylaxis other than enoxaparin 4,000 IU twice daily
- Admission outside the screening period
- Lack of informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Trauma and Reconstructive Surgery
Tübingen, Baden-Wurttemberg, 72076, Germany
Related Publications (3)
Mahmoud SS, Esser M, Jain A. Thromboembolic events in pelvic and acetabulum fractures: a systematic review of the current literature on incidence, screening, and thromboprophylaxis. Int Orthop. 2022 Aug;46(8):1707-1720. doi: 10.1007/s00264-022-05431-z. Epub 2022 May 11.
PMID: 35543748BACKGROUNDWang P, Kandemir U, Zhang B, Wang B, Li J, Zhuang Y, Wang H, Zhang H, Liu P, Zhang K. Incidence and Risk Factors of Deep Vein Thrombosis in Patients With Pelvic and Acetabular Fractures. Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619845066. doi: 10.1177/1076029619845066.
PMID: 31014089BACKGROUNDZhao W, Zhao J, Liu T, Liu Z, Liu L, Zhang Y. Incidence and risk factors of preoperative deep venous thrombosis following pelvic and acetabular fractures: a retrospective case-control study. J Orthop Surg Res. 2022 Feb 5;17(1):77. doi: 10.1186/s13018-022-02972-2.
PMID: 35123537BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Weeks
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 1, 2025
First Posted
September 10, 2025
Study Start
January 1, 2024
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
September 10, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share
De-identified individual participant data (IPD) underlying the results reported in this study will not be made publicly available due to local data protection regulations. Summary-level results will be shared in publications and upon reasonable request to the corresponding author.